Primary Site >> Pancreatic Cancer
Gene >> PDGFRB
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. PMID: 7665222 |
Ref: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. PMID: 14695158 |
Ref: Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. PMID: 15701856 Ref: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. PMID: 16288027 |
Ref: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. PMID: 15893416 Ref: Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? PMID: 16621676 Ref: Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. PMID: 16773192 Ref: Identification of fibroblast heterogeneity in the tumor microenvironment. PMID: 17106243 |
Ref: Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. PMID: 17200369 Ref: Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. PMID: 17641778 |
Ref: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. PMID: 18514780 Ref: Small molecule tyrosine kinase inhibitors in pancreatic cancer. PMID: 19707451 |
Ref: [Treatments of epithelial ovarian cancer by histologic subtype]. PMID: 19223734 Ref: Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. PMID: 19801102 |
Ref: Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. PMID: 21885862 Ref: Activation of PDGFr-beta Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. PMID: 24212821 |
Ref: Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. PMID: 20803052 Ref: A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. PMID: 21750117 Ref: Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. PMID: 22100984 Ref: PDGFRbeta expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. PMID: 22403002 Ref: The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells. PMID: 22479394 Ref: Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. PMID: 22935731 |
Ref: Peptide arrays for development of PDGFRbeta Affine molecules. PMID: 23381728 Ref: Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-beta signalling pathway. PMID: 23950591 |
Ref: Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. PMID: 24528513 Ref: Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. PMID: 24725405 Ref: Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. PMID: 24810090 Ref: Expression of platelet-derived growth factor receptor beta is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis. PMID: 24981766 |
Ref: First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. PMID: 25805799 |
Ref: Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD. PMID: 26831065 Ref: Impact of p53 and PDGFR-beta Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. PMID: 26940582 Ref: The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. PMID: 27374084 Ref: Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. PMID: 27613577 Ref: Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. PMID: 27798861 |
Ref: MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells. PMID: 28196027 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. PMID: 28619758 Ref: Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. PMID: 28838379 |
Ref: Masitinib in treatment of pancreatic cancer. PMID: 29638149 |